Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
**Summary of the SUBLOCADE Long-term Outcomes Trial**
The SUBLOCADE Long-term Outcomes trial is studying the effects of a medication called SUBLOCADE on people recovering from opioid use disorder (OUD). This trial aims to observe how well SUBLOCADE helps individuals over a long period—up to four years—by looking at different aspects of their lives. Researchers want to see how this treatment affects not just the use of opioids but also a person's overall health, social life, and economic situation. By gathering this information, they hope to better understand what helps people recover from opioid addiction.
To participate in this study, you need to be at least 18 years old and have signed a consent form. You should have started receiving SUBLOCADE treatments within the last three months or have completed a previous study involving SUBLOCADE. It’s important that you are not currently taking opioids for any other health reasons and that you are not involved in another clinical trial that requires medical treatment. If you join this study, you can expect regular check-ins to monitor your progress and gather information about your recovery journey. This trial is open to all genders and is currently recruiting participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Participants must meet all of the following criteria:
- • Is an adult ≥ 18 years of age who has signed the informed consent form
- • Plans to receive additional SUBLOCADE injections and
- • Has initiated treatment for OUD/opioid dependence with SUBLOCADE within the last 3 months prior to Baseline Visit
- • OR
- • Has completed an Indivior SUBLOCADE study (eg, INDV-6000-401, INDV-6000-405) and has received the last dose of SUBLOCADE on that study within 3 months prior to Baseline Visit
- • Is not currently participating in any clinical trial requiring medical intervention
- • Is not currently using opioids to treat a diagnosis other than OUD/opioid dependence
About Indivior Inc.
Indivior Inc. is a global pharmaceutical company dedicated to transforming the treatment of addiction and related disorders through innovative therapies. With a strong focus on advancing the science of addiction medicine, Indivior develops and commercializes evidence-based solutions to improve patient outcomes and enhance the quality of life for individuals suffering from substance use disorders. The company's commitment to research and development is underscored by its robust pipeline of clinical trials aimed at addressing unmet medical needs and providing healthcare professionals with effective tools for managing addiction. Through collaboration with healthcare providers and advocacy organizations, Indivior strives to raise awareness and foster understanding of addiction as a chronic disease, promoting a holistic approach to treatment and recovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
New York, New York, United States
Tupelo, Mississippi, United States
Amherst, New York, United States
Richmond, Virginia, United States
Costa Mesa, California, United States
Greenville, South Carolina, United States
Newcastle, New South Wales, Australia
Springfield, Massachusetts, United States
Detroit, Michigan, United States
Surrey, British Columbia, Canada
Hamilton, Ontario, Canada
Houston, Texas, United States
Charlotte, North Carolina, United States
Clinton, Utah, United States
Oklahoma City, Oklahoma, United States
Miami, Florida, United States
Dearborn, Michigan, United States
Prairie Village, Kansas, United States
Baltimore, Maryland, United States
Escondido, California, United States
Miami, Florida, United States
Fair Haven, Michigan, United States
Rockville Centre, New York, United States
Columbia, South Carolina, United States
Sarnia, Ontario, Canada
Miami, Florida, United States
Palmetto Bay, Florida, United States
Toronto, Ontario, Canada
Westport, Connecticut, United States
Sulphur, Oklahoma, United States
Edmonton, Ontario, Canada
Scarborough, Maine, United States
Narberth, Pennsylvania, United States
Calgary, Alberta, Canada
Fitzroy, Melbourne, Australia
Dearborn Heights, Michigan, United States
Decatur, Georgia, United States
Saint Louis, Missouri, United States
Grand Rapids, Michigan, United States
Hialeah, Florida, United States
N. New Hyde Park, New York, United States
Corvallis, Oregon, United States
Newcastle, New South Wales, Australia
Stepney, South Australia, Australia
Owen Sound, Ontario, Canada
Stockholm, , Sweden
North New Hyde Park, New York, United States
Hollywood, Florida, United States
Binghamton, New York, United States
Newcastle, , Australia
Richmond, , Australia
Linköping, , Sweden
Grand Rapids, Michigan, United States
Binghamton, New York, United States
Charleston, South Carolina, United States
Calgary, Alberta, Canada
Hamilton, Ontario, Canada
Stockholm, , Sweden
Richmond, , Australia
Edmonton, Alberta, Canada
Burlington, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported